Natalizumab: clinical use

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

Natalizumab: clinical use. Natalizumab is a humanised monoclonal antibody. Fully referenced neurology checklist.

Mode of action

  • Natalizumab is a humanised monoclonal antibody
  • It binds to α4β1-integrin on the surface of lymphocytes and monocytes
  • It thereby inhibits lymphocyte migration into the central nervous system
  • The effect lasts up to 6 months

Clinical benefits of Natalizumab

Locked: subscribe to see this section.

Dose

Locked: subscribe to see this section.

Acronym

Locked: subscribe to see this section.

References

  1. Dargahi N, Katsara M, Tselios T, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci 2017; 7(7) pii: E78. 
  2. Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ 2016; 354:i3518.
  3. Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med 2017; 65:883-891.
  4. Stuve O, Marra CM, Cravens PD, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy. Arch Neurol 2007; 64: 169-176.
  5. Warnke C, Menge T, Hartung H-P, et al. Natalizumab and progressive multifocal leukoencephalopathy. Arch Neurol 2010; 67:923-930.
  6. And 3 more. Subscribe to see the full list

Related checklists

Loading...